Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors

Journal of Controlled Release

Volumn 216, Issue , 2015, Pages 103-110

  Wang, Jie ^a   Lu, Ze ^a   Wang, Junfeng ^a   Cui, Minjian ^a   Yeung, Bertrand Z ^b   Cole, David J ^c   Wientjes, M Guillaume ^a   Au, Jessie L S ^a,b,c,d  

^a Optimum Therapeutics LLC   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chemo gene therapy; Intravenous siRNA delivery; Paclitaxel; Pancreatic cancer; Survivin

Indexed keywords

CELL DEATH; DISEASES; GENES; LIPOSOMES; NUCLEIC ACIDS; RNA; TUMORS;

BROAD-SPECTRUM ACTIVITIES; DISPERSION OF NANO PARTICLES; PACLITAXEL; PANCREATIC CANCERS; SIRNA DELIVERY; SMALL INTERFERING RNA (SIRNA); SURVIVIN; TRANSFECTION EFFICIENCY;

GENE THERAPY;

DOUBLE STRANDED RNA; LIPOPLEX; PACLITAXEL; SMALL INTERFERING RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; LIPID; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER STAGING; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; DRUG RELEASE; DRUG SOLUBILITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MCF 7 CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS TUMOR; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE SILENCING; GENE THERAPY; GENETIC TRANSFECTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INJECTIONS, INTRAVENOUS; LIPIDS; MICE; MICE, NUDE; PACLITAXEL; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940212902     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.08.012     Document Type: Article

References (40)

1. J.L. Au, S.H. Jang, and M.G. Wientjes Clinical aspects of drug delivery to tumors J. Control. Release 78 2002 81 95
2. S.H. Jang, M.G. Wientjes, D. Lu, and J.L. Au Drug delivery and transport to solid tumors Pharm. Res. 20 2003 1337 1350
3. J. Wang, Z. Lu, M.G. Wientjes, and J.L. Au Delivery of siRNA therapeutics: barriers and carriers AAPS J. 12 2010 492 503
4. F.M. van de Water, O.C. Boerman, A.C. Wouterse, J.G. Peters, F.G. Russel, and R. Masereeuw Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules Drug Metab. Dispos. 34 2006 1393 1397
5. S. Akhtar, and I.F. Benter Nonviral delivery of synthetic siRNAs in vivo J. Clin. Invest. 117 2007 3623 3632
6. Y.K. Oh, and T.G. Park siRNA delivery systems for cancer treatment Adv. Drug Deliv. Rev. 61 2009 850 862
7. Y.C. Tseng, S. Mozumdar, and L. Huang Lipid-based systemic delivery of siRNA Adv. Drug Deliv. Rev. 61 2009 721 731
8. H.J. Kuh, S.H. Jang, M.G. Wientjes, J.R. Weaver, and J.L. Au Determinants of paclitaxel penetration and accumulation in human solid tumor J. Pharmacol. Exp. Ther. 290 1999 871 880
9. S.H. Jang, M.G. Wientjes, and J.L. Au Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule J. Pharmacol. Exp. Ther. 296 2001 1035 1042
10. J.H. Zheng, C.T. Chen, J.L. Au, and M.G. Wientjes Time- and concentration-dependent penetration of doxorubicin in prostate tumors AAPS PharmSci 3 2001 E15
11. D. Lu, M.G. Wientjes, Z. Lu, and J.L. Au Tumor priming enhances delivery and efficacy of nanomedicines J. Pharmacol. Exp. Ther. 322 2007 80 88
12. Z. Lu, M. Tsai, D. Lu, J. Wang, M.G. Wientjes, and J.L. Au Tumor penetrating microparticles for intraperitoneal therapy of ovarian cancer J. Pharmacol. Exp. Ther. 327 2008 673 682
13. H.L. Wong, Z. Shen, Z. Lu, M.G. Wientjes, and J.L. Au Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures Mol. Pharm. 8 2011 833 840
14. J. Wang, Z. Lu, Y. Gao, M.G. Wientjes, and J.L. Au Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming Nanomedicine 6 2011 1605 1620
15. J. Wang, Z. Lu, B.Z. Yeung, M.G. Wientjes, D.J. Cole, and J.L. Au Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors J. Control. Release 178 2014 79 85
16. M. Cui, J.L. Au, M.G. Wientjes, M.A. O'Donnell, K.R. Loughlin, and Z. Lu Intravenous siRNA silencing of survivin enhances activity of mitomycin C in Human bladder RT4 xenografts J. Urol. 194 2015 230 237
17. K. Kami, R. Doi, M. Koizumi, E. Toyoda, T. Mori, D. Ito, K. Fujimoto, M. Wada, S. Miyatake, and M. Imamura Survivin expression is a prognostic marker in pancreatic cancer patients Surgery 136 2004 443 448
18. M.A. Lee, G.S. Park, H.J. Lee, J.H. Jung, J.H. Kang, Y.S. Hong, K.S. Lee, D.G. Kim, and S.N. Kim Survivin expression and its clinical significance in pancreatic cancer BMC Cancer 5 2005 127
19. B.B. Liu, and W.H. Wang Survivin and pancreatic cancer World J. Clin. Oncol. 2 2011 164 168
20. G. Tonini, B. Vincenzi, D. Santini, S. Scarpa, T. Vasaturo, C. Malacrino, R. Coppola, P. Magistrelli, D. Borzomati, A. Baldi, A. Antinori, M. Caricato, G. Nuzzo, and A. Picciocchi Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients Br. J. Cancer 92 2005 2225 2232
21. K. Asanuma, R. Moriai, T. Yajima, A. Yagihashi, M. Yamada, D. Kobayashi, and N. Watanabe Survivin as a radioresistance factor in pancreatic cancer Jpn. J. Cancer Res. 91 2000 1204 1209
22. H.T. Guan, X.H. Xue, Z.J. Dai, X.J. Wang, A. Li, and Z.Y. Qin Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity World J. Gastroenterol. 12 2006 2901 2907
23. K. Kami, R. Doi, M. Koizumi, E. Toyoda, T. Mori, D. Ito, Y. Kawaguchi, K. Fujimoto, M. Wada, S. Miyatake, and M. Imamura Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells Surgery 138 2005 299 305
24. W.S. Liu, H.J. Yan, R.Y. Qin, R. Tian, M. Wang, J.X. Jiang, M. Shen, and C.J. Shi siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity Dig. Dis. Sci. 54 2009 89 96
25. Y.M. Shen, X.C. Yang, M.L. Song, C.H. Qin, C. Yang, and Y.H. Sun Growth inhibition induced by short hairpin RNA to silence survivin gene in human pancreatic cancer cells Hepatobiliary Pancreat. Dis. Int. 9 2010 69 77
26. J. Yang, J. Ouyang, L. Ouyang, L. Ouyang, and Y. Chen Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells Oncol. Res. 21 2013 43 50
27. X. Ling, R.J. Bernacki, M.G. Brattain, and F. Li Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest J. Biol. Chem. 279 2004 15196 15203
28. C.C. Yu, A.L. Woods, and D.A. Levison The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications Histochem. J. 24 1992 121 131
29. Y. Lei, Z. Geng, W. Guo-Jun, W. He, and Y. Jian-Lin Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance Mol. Cell. Biochem. 344 2010 23 31
30. F. Rodel, T. Sprenger, B. Kaina, T. Liersch, C. Rodel, S. Fulda, and S. Hehlgans Survivin as a prognostic/predictive marker and molecular target in cancer therapy Curr. Med. Chem. 19 2012 3679 3688
31. N. Zaffaroni, M. Pennati, G. Colella, P. Perego, R. Supino, L. Gatti, S. Pilotti, F. Zunino, and M.G. Daidone Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer Cell. Mol. Life Sci. 59 2002 1406 1412
32. B.Z. Yeung, Z. Lu, M.G. Wientjes, and J.L.S. Au A pharmacodynamic model of siRNA-mediated gene silencing Proc. Am. Assoc. Pharm. Sci. 2014 2014 W5322
33. K. Bhalla, Y. Huang, C. Tang, S. Self, S. Ray, M.E. Mahoney, V. Ponnathpur, E. Tourkina, A.M. Ibrado, and G. Bullock Characterization of a human myeloid leukemia cell line highly resistant to taxol Leukemia 8 1994 465 475
34. M. Kavallaris, D.Y. Kuo, C.A. Burkhart, D.L. Regl, M.D. Norris, M. Haber, and S.B. Horwitz Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes J. Clin. Invest. 100 1997 1282 1293
35. Z. Lu, M. Tsai, J. Wang, D.J. Cole, M.G. Wientjes, and J.L. Au Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors Curr. Cancer Drug Targets 14 2014 70 78
36. T.K. Yeh, Z. Lu, M.G. Wientjes, and J.L. Au Formulating paclitaxel in nanoparticles alters its disposition Pharm. Res. 22 2005 867 874
37. J.L.S. Au, D. Li, Y. Gan, X. Gao, A.L. Johnson, J. Johnston, N.J. Millenbaugh, S.H. Jang, H.J. Kuh, C.T. Chen, and M.G. Wientjes Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention Cancer Res. 58 1998 2141 2148
38. G. Hu, R.A. Chong, Q. Yang, Y. Wei, M.A. Blanco, F. Li, M. Reiss, J.L. Au, B.G. Haffty, and Y. Kang MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer Cancer Cell 15 2009 9 20
39. D. Pozzi, G. Caracciolo, A.L. Capriotti, C. Cavaliere, B.G. La, T.J. Anchordoquy, and A. Lagana Surface chemistry and serum type both determine the nanoparticle-protein corona J. Proteome 119 2015 209 217
40. D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R.K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, C.E. Van, X. Wei, J. Iglesias, and M.F. Renschler Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N. Engl. J. Med. 369 2013 1691 1703